BRNS Barinthus Biotherapeutics Plc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: BRNS

Price (delayed)

$2.18

Market cap

$84.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.91

Enterprise value

-$44.27M

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed ...

Highlights
Barinthus Biotherapeutics's EPS has increased by 6% from the previous quarter
The net income has grown by 5% from the previous quarter
Barinthus Biotherapeutics's quick ratio has decreased by 31% YoY but it has increased by 31% from the previous quarter
BRNS's revenue has dropped by 98% year-on-year and by 89% since the previous quarter
The gross profit has dropped by 98% year-on-year and by 89% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://vaccitech.co.uk
Peers: OMER OMGA

Key stats

What are the main financial stats of BRNS
Market
Shares outstanding
38.92M
Market cap
$84.85M
Enterprise value
-$44.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
104.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-55.19
Earnings
Revenue
$802,000
EBIT
-$76.39M
EBITDA
-$69.64M
Free cash flow
-$56.34M
Per share
EPS
-$1.91
Free cash flow per share
-$1.47
Book value per share
$4.84
Revenue per share
$0.02
TBVPS
$4.62
Balance sheet
Total assets
$214.51M
Total liabilities
$27.51M
Debt
$12.98M
Equity
$186.78M
Working capital
$144.31M
Liquidity
Debt to equity
0.07
Current ratio
12.45
Quick ratio
11.28
Net debt/EBITDA
1.85
Margins
EBITDA margin
-8,682.9%
Gross margin
100%
Net margin
-9,145.5%
Operating margin
-10,463.1%
Efficiency
Return on assets
-30.8%
Return on equity
-35.2%
Return on invested capital
-244.7%
Return on capital employed
-37.8%
Return on sales
-9,525.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BRNS stock price

How has the Barinthus Biotherapeutics stock price performed over time
Intraday
-0.91%
1 week
-15.18%
1 month
-25.09%
1 year
-8.4%
YTD
-40.92%
QTD
-8.4%

Financial performance

How have Barinthus Biotherapeutics's revenue and profit performed over time
Revenue
$802,000
Gross profit
$802,000
Operating income
-$83.91M
Net income
-$73.35M
Gross margin
100%
Net margin
-9,145.5%
BRNS's revenue has dropped by 98% year-on-year and by 89% since the previous quarter
The gross profit has dropped by 98% year-on-year and by 89% since the previous quarter
BRNS's operating income is up by 6% from the previous quarter
The net income has grown by 5% from the previous quarter

Growth

What is Barinthus Biotherapeutics's growth rate over time

Valuation

What is Barinthus Biotherapeutics stock price valuation
P/E
N/A
P/B
0.45
P/S
104.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-55.19
Barinthus Biotherapeutics's EPS has increased by 6% from the previous quarter
The equity has contracted by 23% YoY and by 4.4% from the previous quarter
The stock's price to book (P/B) is 10% less than its last 4 quarters average of 0.5
The P/S is 107% above the last 4 quarters average of 50.4
BRNS's revenue has dropped by 98% year-on-year and by 89% since the previous quarter

Efficiency

How efficient is Barinthus Biotherapeutics business performance
Barinthus Biotherapeutics's return on invested capital has increased by 9% QoQ

Dividends

What is BRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BRNS.

Financial health

How did Barinthus Biotherapeutics financials performed over time
The current ratio rose by 35% QoQ but it fell by 28% YoY
Barinthus Biotherapeutics's quick ratio has decreased by 31% YoY but it has increased by 31% from the previous quarter
The debt is 93% lower than the equity
BRNS's debt to equity has soared by 75% year-on-year
The debt is up by 48% YoY and by 2.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.